Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

A father takes his daughter to her favorite pop star's concert only to realize they're caught in an FBI sting operation to catch a serial killer. An exotic dancer's fate takes a turn when she crosses ...